Introduction {#S1}
============

Heart failure (HF) is a leading, growing public health problem, affecting millions of people worldwide ([@B87]). Most cases of HF are the result of a myocardial infarction (MI), defined as massive cardiac muscle death due to ischemia as a consequence of temporary or permanent blockage of blood supply to the myocardium, generally originated by thrombosis ([@B86]; [@B58]; [@B41]; [@B164]). The cardiac cell death and blood vessel damage lead to extensive inflammatory responses followed by wound healing.

The human heart has only a modest capability to replace the damaged tissue and restore functionality after MI. Conversely, in the case of lower vertebrates, including some fish and amphibian species, regenerative capacity is retained throughout adult life without evidence of scarring ([@B116]; [@B143]; [@B19]; [@B77]). It was also shown that neonatal mammalian hearts, including mice ([@B141], [@B142]), rats, and even humans ([@B65]), can exhibit the ability to regenerate and functionally recover in several injury models, in a limited time window immediately after birth. Genetic fate mapping in zebrafish and neonatal mice revealed that endogenous heart repair was achieved by the proliferation of pre-existing cardiomyocytes (CMs), not by the mobilization of undifferentiated precursors ([@B77]; [@B82]). However, the human adult heart consists mostly of terminally differentiated CM, excluding a small subpopulation of cardiac stem cells involved in maintaining cellular homeostasis ([@B183]). In light of these differences, following injury the damaged portions are vastly replaced by a rigid, collagenous fibrotic scar to avoid cardiac rupture ([@B123]; [@B135]). The outcome of the wound healing process is a mechanically inferior cardiac muscle, unable to function sufficiently and mostly followed by sequential HF. Other pathologies may also impair the heart's ability to function sufficiently and lead to HF, including valvular disease, hypertension, genetic cardiomyopathies, or aging, which cause slow functional cell loss over time.

Currently, the most common clinical intervention after MI resulting from blood vessel occlusion includes rapid re-perfusion to minimize CM death ([@B59]). Primary percutaneous coronary intervention (PCI) is the preferred procedure to treat narrowing or blockage of coronary arteries (stenosis). Nonetheless, a quick diagnosis (\<90 min from first medical contact) of acute MI symptoms is required in order to make this strategy effective ([@B103]; [@B18]). In the case of end-stage heart conditions, whole heart transplantation remains the only option for heart function regeneration. However, the insufficient number of donors (approximately 4000 patients on a waiting list in the US as of April 2018) and abundant post-transplantation complications limit the implementation of this strategy ([@B15]).

In this review, the intrinsic restraints behind endogenous cardiac regeneration following cardiac injury will be presented, defining five main target processes for therapeutic interventions. Next, cardiac regeneration strategies and limitations, namely cell-based therapies and exogenous administration of bioactive molecules will be discussed. Finally, the biomaterial-based tissue engineering approach will be introduced, focusing on current therapeutic applications of endogenous cardiac regeneration, remaining challenges and future perspectives.

Endogenous Cardiac Regeneration Limitations {#S1.SS1}
-------------------------------------------

The main obstacle on the way to recovery from myocardial injury is the poor endogenous regenerative capacity of the adult mammalian heart. Cardiac regeneration is limited mainly since the majority of adult CMs do not proliferate. Shortly after birth, the cardiac tissue mechanism of growth shifts from hyperplasia to hypertrophy, meaning cell enlargement ([@B48]). A major aspect of this transition is that most CMs in the mammalian myocardium withdraw from the cell cycle and grow 30--40 times in mass ([@B100]). Proliferating cell populations were found to present negligible turnover rates (\<1% per year and decreasing with age) ([@B16]). Even though there are evidences for cardiac progenitor cells (CPCs) or stem cells (CSC) residing in the adult myocardium, these subpopulations are considered minuscule (approximately 1 cell per 13,000 myocytes) ([@B183]). Even though these cell populations were observed to increase dramatically in number after MI, almost 50% exhibited a senescent phenotype, incapable of cycling and differentiating ([@B187]). In addition, recruitment and activation of these cells is inadequate to lead to cardiac repair due to physical barriers and lack of appropriate signaling ([@B161]). Overall, these attributes result in insufficient intrinsic regenerative potential, unable to compensate for the extensive loss of heart muscle cells.

Consequently, the adult myocardium responds to MI by two main mechanisms: (a) The formation of a fibrotic scar through a wound healing process and (b) hypertrophic remodeling of the surviving myocardium ([@B179]; [@B41]). These structural changes markedly increase the mechanical stress on the ventricular wall and promote progressive contractile dysfunction, eventually leading to HF ([@B161]).

Major Target Processes to Promote Cardiac Regeneration {#S1.SS2}
------------------------------------------------------

Considering the poor intrinsic capability of the adult heart to properly regenerate, key hallmarks of adult heart post-MI must be overcome. Achieving effective cardiac regeneration should include tissue recovery following injury (meaning cell survival), overturn or attenuation of tissue remodeling and fibrosis, and myocardium renewal via formation of new myocardium and blood vessels. Therefore, the therapeutic strategy could target each or all the following five major processes associated with MI:

1.  Cardioprotection -- prevention of resident CMs massive death (up to 1 billion cells) post-MI, by inhibition of apoptotic signaling pathways and/or induction of pro-survival signals ([@B57]; [@B1]).

2.  Inflammation -- in response to ischemia, necrotic CM signaling initiates a pro-inflammatory response, in order to remove remaining cell debris. The second phase includes an anti-inflammatory response, the purpose of which is to allow wound healing and scar formation. The shift between each of these responses is tightly regulated by multiple interactions between cellular myocardium components and the immune system. Manipulation of the time frames of the pro-/anti-inflammatory response after MI by changing the chemokine/cytokine profile or cellular responses may allow proper tissue repair to occur rather than the undesired results of an excessive inflammation, including cell death and scarring ([@B51]; [@B135]).

3.  Extracellular matrix (ECM) remodeling and cardiac fibrosis -- attenuation of the fibrotic response, meaning ECM composition changes and scar formation, by altering pro-fibrotic signaling pathways. This includes inhibition of matrix metalloproteinases (MMPs) or changes in balance between MMPs and tissue residing inhibitors, in order to slow down scarring in favor of desired tissue healing ([@B93]; [@B49]).

4.  Angiogenesis and vascularization -- formation of new blood vessels to allow appropriate nutrient supply to the ischemic regions. This could be achieved by induction of pro- angiogenesis signals, including proteins, endothelial cell (EC) recruitment, and altering inflammation and scarring ([@B149]).

5.  Cardiomyogenesis -- To fully restore cardiac function, it is essential that the infarct zone will be replaced by regenerated myocardium, which could involve proliferation of CPCs/CSCs, proliferation of adult CMs via induction of cell-cycle re-entry, and/or exogenous transplantation of CMs/CPCs ([@B126]).

Cardiac Regeneration Strategies and Challenges {#S2}
==============================================

Cell-Based Therapies {#S2.SS1}
--------------------

Several approaches to repair or replace injured cardiac tissue were suggested over the last two decades. One of them is the cell-based therapy, namely injection of a cell suspension. The concept is to use an engraftment of cardiac cells to reconstruct the lost muscle tissue. Injection of these suspended cells directly into the myocardium could attenuate myocardial deterioration and dysfunction.

This application requires the use of cell sources capable of yielding mature and functional CMs. Furthermore, the transplanted cells should be of autologous origin or immunotolerated by the host. Several cell sources were suggested for this purpose. CPCs/CSCs, assumed to naturally occupy the adult myocardium, are one subpopulation capable of self-renewal and differentiation. Yet, harvesting these cells requires their isolation from a myocardial biopsy, followed by cell expansion, thus limiting their availability for transplantation when treating acute MI ([@B183]).

In the last decade, human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) have been considered the most attractive stem cell types as a source for *de novo*, mature CM production. Both cell types can be differentiated into CMs *in vitro* ([@B138]; [@B101]), while also having limitless cell division capability. Yet, both hESCs and iPSCs present some limitations. For instance, the origin of hESCs from blastocyst inner cell mass raises some ethical issues, along with a risk of eliciting an immune response due to their allogeneic nature ([@B11]). iPSCs are considered less immunogenic since these cells are derived from somatic cells, which potentially could be autologous to the patient. Another concern regarding the use of both types of these cells for transplantation is their pluripotency. Incomplete differentiation or ineffective isolation of the desired cell population could eventually lead to the formation of teratomas after transplantation ([@B133]).

Nonetheless, this strategy alone presents very limited clinical impact due to low cell survival and retention rates inside the injected heart, resulting in only up to 10% of the delivered cells surviving 24 h after transplantation. Hence, to become clinically relevant, this kind of strategy demands the injection of an enormous number of cells ([@B121]; [@B64]; [@B199]). Besides cellular retention, cells injected within a suspension are lacking an optimal microenvironment, provided naturally by surrounding ECM. In order to reconstruct tissue organization and functionality, it is essential to supply the cells with appropriate mechanical support, topographical guidance, and proper biochemical signaling to allow desired tissue organization, differentiation, and maturation *in situ* ([@B52]; [@B70]; [@B50]).

On another note, the exact role of the injected cells in inducing cardiac regeneration is still not fully understood -- do these cells act as a substitute at the injured portions of the myocardium, or perhaps, as some researchers suggest, injected cells mainly act in a paracrine manner, introducing secreted ECM and signaling molecules to surrounding host myocardium, a theory also known as "the paracrine hypothesis" ([@B119]). Mesenchymal stem cell (MSC) therapy is a predominant example for this mechanism of action ([@B60]; [@B194]). MSCs, which present only limited ability to *trans*-differentiate into CMs *in vivo* ([@B174]), were shown to secret signaling molecules improving cell survival, modulating immune response, and even inducing angiogenesis ([@B140]; [@B181]; [@B194]). Although this approach was already examined in several clinical trials, evaluating different aspects of MSC delivery and their origin, it still presents major concerns limiting its efficacy. From the technical point of view, use of autologous MSCs requires their isolation and further expansion in order to be transplanted, which limits their applicability in an acute setting ([@B177]). Some clinical trials, but not all, have also highlighted safety issues, including the possibility of malignant tumor formation ([@B75]) and paracrine proarrhythmic effects ([@B7]) post transplantation.

Recently, it was demonstrated in an ischemia mice model that the marginally improved heart function after stem cell therapy is mostly attributed to the induction of acute immune response rather than proliferation of transplanted or endogenous CMs. [@B188] showed that the functional benefit underlying this strategy is inflammatory-based wound healing and attenuation of fibrosis, suggesting that the moderate improvement in cardiac function observed in the past corresponds better with the paracrine hypothesis.

Bioactive Molecules {#S2.SS2}
-------------------

Assuming the "paracrine effect" is the engine behind cardiac regeneration, an opposing strategy to cell injection is based on the administration of bioactive signaling molecules. Three main classes of secretory factors were identified to induce cardiac regeneration, covering most of the targets specified above: growth factors (GFs) (i.e. cytokines/chemokines), non-coding RNA (i.e. microRNAs (miRNAs) and small interference RNA), and extracellular vesicles (EVs) (i.e. microvesicles and exosomes).

### Growth Factors {#S2.SS2.SSS1}

Growth factors are signaling molecules, mostly proteins, which were identified to participate in various cellular processes. For example, insulin-like GF 1 (IGF-1) was previously shown to delay cellular aging and promote cell survival, while also benefit angiogenesis ([@B184]). Vascular endothelial GF (VEGF) is another cardiac-regenerating inducer; it was demonstrated to improve viability of cardiac tissue and reduce infarct size post-MI in multiple animal models through pro-angiogenic and cardiomyogenic effects ([@B46]; [@B74]). Activation of the ERBB2/ERBB4 signaling pathway by neuregulin 1 (NRG1) administration has also shown regenerative potential, driven by induction of CM proliferation ([@B17]; [@B36]).

Nevertheless, the effect of systemic/local administration of GFs was inconsistent in clinical trials, showing no beneficial effects ([@B175]; [@B2]). This could be explained by an insufficient amount of the therapeutic molecules at the target site, obligating usage of higher dosage of GFs or, alternatively, the use of a proper delivery vehicle to overcome issues of fast elimination, low protein stability, and unspecific delivery ([@B157]). Another concern is the pleiotropic functions that most cytokines have, which further encourage the use of a delivery system for their local and scheduled administration.

### MicroRNAs {#S2.SS2.SSS2}

MicroRNAs are short (∼22 nucleotides long), non-coding, single stranded RNAs. Most commonly, these RNA molecules are inhibitors of protein expression, by interacting with specific mRNA in the cytoplasm, subsequently leading to mRNA cleavage or repression of translation ([@B88]). Numerous studies have connected miRNAs and various cardiovascular diseases, showing that miRNA expression levels were altered in MI, cardiac hypertrophy, and HF. Therefore, over the last decade miRNAs have become a therapeutic target for treatment of cardiovascular diseases ([@B12]). For instance, [@B44] performed a functional screening study to identify which human miRNAs can promote CM proliferation at neonatal stages. Two of these miRNAs, miR-199a-3p and miR-590-3p, were further demonstrated to induce cardiac regeneration in an adult mouse MI model.

Besides CM proliferation, miRNAs were shown to affect other target processes associated with MI, including miR-21, which could modulate inflammation processes and reduce CM apoptosis ([@B33]; [@B43]). Inhibition of miRNAs is also a possibility as demonstrated by [@B127]. By subcutaneous delivery of an antisense oligonucleotide they were able to inhibit miR-208a in the heart, improving cardiac function. In a preclinical trial, a catheter-based administration of a miR-92a inhibitor significantly reduced infarct size, while also excreting cardioprotective, proangiogenic, and anti-inflammatory effects ([@B145]).

Even though miRNAs are normally detected outside the cell in body fluids, circulating miRNAs are at risk to be cleaved by RNases in these biofluids. Moreover, the strong negative charge of soluble nucleic acids results in inadequate cellular uptake ([@B148]). Hence, it is essential to use proper vehicles to deliver miRNA, keeping it stable and protected from degradation in the extracellular environment ([@B22]). Safety issues are also a concern when applying constitutive expression of miRNAs, as in the case of adeno-associated virus (AAV) delivery. Such a delivery strategy presents the risk of unwanted pathologies, such as uncontrolled heart growth ([@B56]) or undesired, off-target transfection (e.g. in the liver) ([@B108]). Therefore, it is required for miRNA delivery to be time-limited and controlled.

### Extracellular Vesicles {#S2.SS2.SSS3}

Extracellular vesicles are emerging, natural carriers that could potentially deliver miRNA. These are small, membrane-enclosed vesicles that are generated and secreted by living cells. One class of EVs are exosomes, classified as double-membraned vesicles that range between 30 and 150 nm in diameter ([@B30]). Exosome content usually includes proteins, mRNA and miRNA.

It has been well documented that exosomes are used for communication between cells ([@B176]); prominent examples can be found in cancer cells ([@B193]; [@B27]) and in the cardiovascular system ([@B40]). More recently, exosomes secreted by different sources of stem cells were compared to assess their potential for inducing cardiac repair in a MI model. Analysis of miRNA repertoire in exosomes secreted by iPS-derived CMs and hESCs-CMs revealed that miRNA content included some miRNAs that are known to be cardioprotective ([@B96]).

Exosomes from other cell types originating from the cardiovascular system were also shown to have potential to improve cardiac repair. For instance, monocyte-derived exosomes were shown to affect migration of ECs via exosomal transfer of miR-150, promoting angiogenesis ([@B208]), while CPCs were demonstrated to stimulate regeneration and improve cardiac function via secretion of exosomes ([@B72]; [@B39]). The MSCs secretome was also widely investigated for its therapeutic potential, as the experience with clinical trials demonstrated only limited effects of MSC transplantation. Administration of MSC-derived exosomes contributed to cell survival, reduced inflammation, and decreased oxidative stress *in vitro* and *in vivo* ([@B6]; [@B45]). Another possibility is loading exosomes with specific cargo ([@B109]), enriching them with either drugs ([@B178]), proteins ([@B78]), or miRNAs ([@B204]). This approach could be used to manipulate exosome cargo and turn them into therapeutic agents, to be internalized by target cells and deliver desired molecules for treating different pathologies in these cells.

Even though exosome-based delivery eases the uptake by target recipient cells and is not considered toxic, it is still lacking the ability of having a long-lasting effect. Much like cytokines, exosomes have a short half-life, due to a rapid cellular internalization rate, therefore narrowing their effect to a limited time window ([@B83]).

Biomaterial-Based Tissue Engineering Approach {#S3}
=============================================

The challenges presented by both cell-based therapies and cardiac regenerating agent delivery have set the stage for the emergence of cardiac tissue engineering (CTE). In general, TE strategies suggest using biomaterials, mostly in combination with bioactive molecules and/or a cell source for regeneration ([@B92]). The rich repertoire of natural and synthetic polymers TE application could utilize for cardiac TE and the relevant criteria for such application were already reviewed in details elsewhere ([@B63]; [@B25]; [@B21]; [@B130]; [@B147]), therefore will not be addressed in the current review. Nevertheless, in the context of CTE, biomaterials can give solutions for both cell-based therapies and applications involving bioactive molecules ([Figure 1](#F1){ref-type="fig"}).

![Biomaterial-based applications for cardiac tissue engineering. **(A)** Biomaterials can be injected alone into the infarcted regions in order to attenuate scar formation, **(B)** cell-delivery using injectable hydrogels can improve cell retention and survival after transplantation; **(C)** three-dimensional matrices can be fabricated with or without cells, then implanted as cardiac patches to improve cardiac function; and **(D)** biomaterials designed to release drugs and bioactive molecules may induce cardiac regeneration in a sustained effective manner.](fbioe-08-00126-g001){#F1}

The traditional applications of TE destinate biomaterials the role of a three-dimensional scaffold for cell retention ([@B90]). Biomaterial-based scaffolds provide the cells with needed mechanical, topographical, and biochemical stimuli, acting as ECM replacement ([@B201]). On that basis, biomaterial scaffolds were investigated in a plethora of studies for *ex vivo* cell cultivation, reviewed in [@B53] and [@B168]. These ECM properties, mimicked by biomaterials, are also of great significance when applying cell-based therapies ([@B97]).

Biomaterials, in the form of injectable hydrogel scaffolds, can be used as a vehicle to deliver cells to the target infarct zone ([@B202]; [@B195]; [@B155]). In parallel, the hydrogel provides the cells with the missing anchoring positions and biophysical cues, this until the cells produce their own ECM, reconstruct their microenvironments and guide their reorganization into a 3D tissue *in situ* ([@B38]; [@B70]).

Moreover, hydrogels embody an additional, important benefit for CTE strategies, as their injection alone into the infarct zone also reduces wall stress (Laplace law) by thickening the scar ([@B28]; [@B89]; [@B186]). Mechanically weak, natural biomaterials are the most investigated hydrogels for this application, including collagen ([@B118]), alginate ([@B89]; [@B162]), hyaluronic acid (HA) ([@B152]), and decellularized myocardial matrix ([@B167]). In the case of the latter, it was postulated that myocardial hydrogels also have effect at the transcription level, inducing regenerative processes following their injection ([@B192]). The application of mechanically strong, fully synthetic biomaterials was also beneficial ([@B32]; [@B115]). Several studies, including those conducted in large animal models of MI, have shown that injection of hydrogel was effective at preventing negative tissue remodeling and improving left ventricular function post-MI, as evident by reduction in the degree of interstitial fibrosis and thickening of infarcted wall ([@B32]; [@B98]; [@B152]).

Biomaterials are also commonly used for the purpose of drug delivery vehicles ([@B85]; [@B153]; [@B68]). Various polymeric materials could be used to encapsulate or entrap bioactive molecules, forming small dimension-particles (microns to sub-nano scale). Such particles enable the delivery of soluble and insoluble bioactive molecules to their target site, increasing stability, elongating drug shelf life, improving drug safety, and specificity ([@B153]).

Drug delivery platforms could also be fabricated from biomaterials, as a standalone application or incorporated with delivery vehicles. Biomaterial mechanical properties could be designed and tailored using different fabrication methods and by chemical formulation and modifications ([@B182]; [@B203]). Therefore, such matrices could release drugs through various mechanisms, depending on their degradation/erosion rate, exogenous triggers, or environment conditioning ([@B197]). This idea is an expansion of the microenvironment mimicry concept. Neighboring cells in the natural microenvironment communicate with each other by paracrine pathways, mediated by secreted proteins, small RNA species, and EVs. The ECM also acts as a reservoir system of signaling molecules ([@B71]; [@B67]). Incorporation of proteins and protein-binding features into biomaterials could resemble another ECM function and elicit desired cellular responses, such as cell proliferation, migration, and differentiation. Therefore, biomaterials originated ([@B170]) or inspired ([@B55]) by ECM components and biomechanical properties are potential candidates to perform as sophisticated drug delivery systems for spatial--temporal presentation and release of therapeutic agents, essential for endogenous tissue regeneration.

All these advantages are already implemented in biomaterial-based strategies meant to improve cardiac regeneration and restore functionality post cardiac injuries. In the following section, four main classes of biomaterial-based approaches will be reviewed: (a) bioactive nano-carriers; (b) hydrogel-assisted cell delivery, (c) cardiac patches, and (d) drug delivery platforms ([Figure 2](#F2){ref-type="fig"} and [Table 1](#T1){ref-type="table"}).

![Biomaterial-based applications for cardiac regeneration. **(A)** Natural or synthetic polymers can be used as nano-carriers for the delivery of cardiac inducing agents. This will assist their bioavailability, allow specific targeting to the infarcted region or destination cell population, and increase their half-life in the tissue, eventually improving treatment efficacy; **(B)** hydrogel systems can be utilized to protect transplanted cells from the hostile post-MI microenvironment. This strategy can improve cell retention and provide the transplanted cells and the infarcted tissue the mechanical support lost as a result of massive loss of muscle tissue; **(C)** biomaterials can be used to fabricate cellular or acellular cardiac patches, providing cell with ECM interactions, mechanical and electrical stimuli. Depending on their size and mechanical properties, cardiac patches can perform as temporary or permanent replacements for damaged tissue; **(D)** regeneration-inducing agents can be encapsulated or bound to biomaterial-based delivery platforms, allowing effective release of these agents in a spatial--temporal manner. Plus sign indicates benefits of the application, arrow indicates an attribute that improves.](fbioe-08-00126-g002){#F2}

###### 

Summary of biomaterials-based applications, advantages, and limitations (selected studies).

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Application**                   **Biomaterial (formulation)**                              **Delivered component**     **Animal model**   **Advantages**                              **Limitations**                             **Study**
  --------------------------------- ---------------------------------------------------------- --------------------------- ------------------ ------------------------------------------- ------------------------------------------- ----------------
  Hydrogel-assisted cell delivery   Alginate, chitosan/β-glycerophosphate (Hydrogel)           MSCs                        Rat                • Cell retention↑\                          • Requires large cell quantities\           [@B151]
                                                                                                                                              • Protection from harsh microenvironment\   • Limited nutrient supply\                  
                                                                                                                                              • Mechanical support↑\                      • Electrical coupling with the host         
                                                                                                                                              • Tissue integration↑                                                                   

                                    Chitosan (Hydrogel)                                        MSCs                        Rat                                                                                                        [@B107]

                                    Fibrin (Hydrogel)                                          Skeletal myoblasts          Rat                                                                                                        [@B26]

                                    Gelatin (Hydrogel)                                         MSCs                        Mouse                                                                                                      [@B62]

                                    RGD modified, self-assembling peptide (Hydrogel)           hESCs-CMs                   Mouse                                                                                                      [@B9]

  Bioactive nano-carriers           Alginate/hyaluronan sulfate (NPs)                          HGF, IGF-1                  Rat                • Half-life↑\                               • Requires high dosages\                    [@B160]
                                                                                                                                              • Drug absorbance↑\                         • Cytotoxicity and immunogenic response\    
                                                                                                                                              • Protection from degradation\              • Undesired accumulation                    
                                                                                                                                              • Specificity and targeting↑\                                                           
                                                                                                                                              • Persistence and effect↑\                                                              
                                                                                                                                              • Invasiveness↓                                                                         

                                    Alginate sulfate (NPs)                                     miR-21                      Mouse                                                                                                      [@B13]

                                    Peptide modified, CSC-exosomes                             miRNAs, proteins            Rat                                                                                                        [@B190]

                                    mESC-exosomes                                              miRNAs, proteins            Mouse                                                                                                      [@B80]

                                    Liposomes                                                  miR-199a-3p, miR-590-3p     Adult mouse                                                                                                [@B139]

                                    RGD modified, PEGylated lipid (NPs)                        Puerarin                    Rat                                                                                                        [@B34]

                                    Peptide modified, PEGylated liposomes                      --                          Mouse                                                                                                      [@B37]

                                    MMP-specific peptide -- polynorbornene amphiphiles (NPs)   --                          Rat                                                                                                        [@B132]

  Cardiac patches                   Alginate (Scaffold)                                        Fetal cardiac cells         Rat                • Cell retention↑\                          • Requires surgery\                         [@B97]
                                                                                                                                              • Protection from harsh microenvironment\   • Immunogenic response\                     
                                                                                                                                              • Mechanical support↑\                      • Limited nutrient supply\                  
                                                                                                                                              • Provides complex 3D architecture\         • Electrical coupling through large areas   
                                                                                                                                              • Cell fate guidance\                                                                   
                                                                                                                                              • Replacing large tissue portions                                                       

                                    RGD-/HBP-modified alginate (Scaffold)                      hESCs-CMs                   --                                                                                                         [@B166]

                                    Decellularized cardiac ECM--gelatin composite (Scaffold)   CPCs                        Rat                                                                                                        [@B14]

                                    Fibrin (Scaffold)                                          hESCs-cardiac progenitors   Human                                                                                                      [@B122]

                                    Fibrinogen (Scaffold)                                      hiPSCs-CMs                  Swine                                                                                                      [@B104]

                                    Chitosan--polyaniline composite (scaffold)                 --                          Rat                                                                                                        [@B79]

                                    Polyurethane--ECM composite (Scaffold)                     --                          Rat                                                                                                        [@B29]

                                    Fibrinogen (Scaffold)                                      hiPSCs-CMs                  Swine                                                                                                      [@B104]

                                    Chitosan--polyaniline composite (scaffold)                 --                          Rat                                                                                                        [@B79]

                                    Polyurethane--ECM composite (Scaffold)                     --                          Rat                                                                                                        [@B29]

                                    Porcine small intestine submucosa ECM (Scaffold)           --                          Pig, ovine                                                                                                 [@B124]; [@B8]

  Drug delivery platforms           Alginate-alginate sulfate (Hydrogel)                       Cytokines                   Rat                • Sustained drug release\                   • Biomaterial clearance\                    [@B160]
                                                                                                                                              • Persistence and effect↑\                  • Immunogenic response\                     
                                                                                                                                              • Protection from degradation\              • Inapplicable for chronic conditions       
                                                                                                                                              • Local delivery\                                                                       
                                                                                                                                              • No cellular component required                                                        

                                    Collagen (Hydrogel)                                        iPSC-CM-derived EVs         Rat                                                                                                        [@B105]

                                    Hyaluronic acid (Hydrogel)                                 miR-302/367 cluster         Rat                                                                                                        [@B191]

                                    PEG (Hydrogel)                                             Erythropoietin, iPSC-CMs    Rat                                                                                                        [@B24]
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CMs, cardiomyocytes; MSCs, mesenchymal stem cells; ESCs, embryonic stem cells; iPSCs, induced pluripotent stem cells; EVs, extracellular vesicles; NPs, nanoparticles; ECM, extracellular matrix; HGF, hepatocyte growth factor; IGF-1, insulin-like growth factor.

Therapeutic Applications of Biomaterials in Cardiac Regeneration {#S4}
================================================================

Nano-Carriers of Bioactive Molecules {#S4.SS1}
------------------------------------

Many efforts were invested to improve the delivery of regeneration inducing agents, mainly in the means of treatment safety, efficacy, and specificity. Nano-carriers can be generally divided into two classes: nanoparticles (NPs) and natural or bio-inspired biomolecule carriers.

### Nanoparticles {#S4.SS1.SSS1}

Polymer-based NPs could come in many forms, including polymeric chains enveloping therapeutic drugs, polymer--macromolecule conjugates or drugs encapsulated in polymeric micelles ([@B35]). These macromolecular structures are of great pharmaceutical importance when the delivered agent has a very short half-life in circulation, or its systemic delivery is accompanied with some cytotoxicity or undesired side effects ([@B153]). The advantages of such nano-carriers were demonstrated in the case of the antioxidant drug Puerarin (PUE), an FDA approved drug for various cardiovascular diseases, including MI ([@B106]). [@B34] developed a micelle-forming polymeric vehicle, administered intravenously and modified with Arg--Gly--Asp (RGD) peptide to increase specificity to the ischemic region. The fabricated NPs were shown to improve PUE pharmaceutical properties, including a threefold increase in half life and drug absorbance, assessed by area under the curve (AUC). Moreover, this formulation was successful at reducing infarct size in a rat MI model, presenting an enhanced effect when RGD modification was added to its surface ([@B34]).

Nanoparticles were also shown to improve protein bioavailability and decrease their toxicity due to supraphysiological dosage ([@B189]). For example, affinity-binding alginate can form nano-scale polymer--protein complexes ([@B156]). Sulfated alginate (AlgS) was previously demonstrated to interact with heparin-binding proteins with similar affinity to heparin ([@B55]). [@B159] showed that AlgS can co-assemble with heparin-binding proteins to form injectable NPs that protect the proteins from degradation.

Nucleic acids delivered systemically (e.g. small RNA species, mRNA, and plasmid DNA) are subjected to fast elimination and/or degradation, while also facing difficulties to enter their target cells ([@B148]; [@B76]). Even though viral vectors are effective for delivering these agents, their application also carries significant safety issues. Thus, non-viral vehicles have emerged as a promising alternative. One of the suggested strategies is using complexes of small RNA (i.e. small interference RNA and miRNA) and plasmid DNA with calcium ions, based on electrostatic interaction between them, resulting in the formation of mildly anionic NPs ([@B158]; [@B61]). When these components were mixed with alginate or hyaluronan sulfate, they also spontaneously assembled into NPs mediated by ion bridges ([@B84]). The incorporation of a polymeric material to the complex enabled the addition of surface features to the resulting NPs using chemical modifications, important for targeting. These NPs were tested in order to attenuate inflammatory response and promote cardiac regeneration in a small animal MI model. In this study, miR-21 mimic was delivered in these NPs, aiming to switch macrophage phenotype to a reparative one during the innate immune system response to MI ([@B13]). Following intravenous administration of the NPs delivering the miR-21 mimic, the particles were shown to target macrophages in the infarcted zone and change their phenotype, resulting in reduced cell apoptosis, fibrosis, and hypertrophy.

### Bio-Inspired Carriers {#S4.SS1.SSS2}

The second class of nano-carriers utilizes natural existing delivery vehicles. One example for such carriers are liposomes, closed bilayer phospholipid systems, inspired by the cellular membrane. Liposomes have been investigated for over half a century, and have been applied in very sophisticated drug delivery systems for proteins and nucleic acids, reviewed in details by [@B4]. In a study looking for alternatives for the use of viral vectors for miRNA mimics delivery, [@B139] assessed the efficacy of different liposomes at inducing cardiac regeneration through CM proliferation mechanism. Since liposomes lack the intrinsic ability to specifically target the heart, they used a local, intracardiac injection to deliver the liposomes straight to the infarcted area, resulting in almost 40% reduction in infarct size.

Liposomes can be targeted to the infarcted region by conjugation of specific ligands overexpressed in infarcted hearts. Such strategy was demonstrated by [@B37], exploiting the change in angiotensin II type 1 (AT1) receptor expression levels after hypoxia to specifically target the MI zone. They modified PEGylated liposomes' surface by addition of a short peptide, similar on one end to angiotensin II (a ligand of AT1 receptor). Then, they showed that the NPs specifically accumulated in the left ventricular wall 7 days post-MI, but not in healthy hearts. These findings were of great significance, since they indicated not only successful targeting that increases treatment efficacy, but also passively target the heart in case of future HF ([@B37]).

Hydrogel-Assisted Cell Delivery {#S4.SS2}
-------------------------------

Improvement of cell retention is one of the key requirements in cell-based therapies ([@B120]). Biomaterials support the transplanted cells, protecting them from the harsh environment of the infarcted region. We were among the first groups to report on a successful implantation of cardiac cell-seeded porous alginate scaffolds into infarcted rat hearts. We found that the seeded fetal rat cardiac cells retained viability within the scaffolds and within 24 h formed multicellular beating cell clusters. Following implantation of the cellular constructs into the infarcted myocardium, some of the cells appeared to differentiate into mature myocardial fibers. The graft and surrounding area were populated with a large number of newly formed blood vessels, consequently leading to attenuation in LV dilatation and improved heart function ([@B97]). An additional group demonstrated this concept using an injectable fibrin scaffold for myoblast delivery into infarcted hearts. An examination of cell location 5 weeks post injection indicated that cells injected in hydrogel were still present in the infarcted region, compared to cells suspended in BSA, which were located solely at the border zone ([@B26]). Another study demonstrated that cell viability was improved following cell administration using alginate and chitosan/β-glycerophosphate hydrogels compared to saline, showing a superior 50--60% cell retention, 24 h post transplantation ([@B151]). Since then, a variety of biomaterials and cell types were tested for cell delivery, reviewed elsewhere ([@B134]).

Hydrogel design criteria for cardiac cell delivery should include three key parameters: (a) mechanical stiffness of injected hydrogel; (b) physical and biochemical microenvironment suitable for encapsulated cells; and (c) duration of cell retention post transplantation. For hydrogels to withstand the mechanical demands required for myocardial applications, their stiffness modulus should be between 20 and 0.1 kPa ([@B147]). On the other hand, biomaterial elasticity could also have a role in stem cell fate determination, including differentiation ([@B42]). In case stem cells are delivered, it is mandatory to consider the use of a hydrogel system with mechanical properties resembling the myocardium in order to avoid differentiation into the wrong lineage.

Nevertheless, the microenvironment provided by the encapsulating matrix is also important in directing cell fate. Biochemical cues, including matrix-anchoring features, have a beneficial effect on cell survival and maturation. In a study aimed at enhancing engraftment of hESC-derived CMs, researchers developed a hydrogel system composed of self-assembling peptides, incorporated with RGD residue. This hydrogel not only increased cell retention in the infarcted heart, it also induced transplanted cells' maturation and integration with the host, evident by expression of mature phenotype and formation of gap junctions with host CMs ([@B9]).

The duration of cell survival post transplantation depends on the mechanism by which the delivered cells promote regeneration. If cell transplantation aims to replace damaged tissue (e.g. CPCs, ESCs/iPSCs derived CMs), the degradation profile should allow cell integration into host myocardium (\>10 days). However, if transplanted cells act by a paracrine effect (e.g. stem cells), the biomaterial should support cell survival for enough time to be effective ([@B99]). For example, the efficacy of MSC-based therapy is dependent on the number of cells surviving after transplantation ([@B3]). Therefore, efforts have been made in order to protect cells upon delivery, using hydrogels to encapsulate MSCs, protecting them for a prolonged time from the hostile microenvironment of the ischemic region, including reactive oxygen species ([@B107]), phagocytosis, and inflammation ([@B62]).

Cardiac Patches {#S4.SS3}
---------------

### Cellularized Patches {#S4.SS3.SSS1}

The holy grail of CTE is the fabrication of a fully developed, three-dimensional (3D) functioning heart tissue, developed *ex vivo* and ready for transplant. In the context of cardiac malfunction, such patches could be used to replace large portions of the injured heart ([Figure 3](#F3){ref-type="fig"}; [@B102]; [@B205], [@B206]). Many cardiac patch designs place emphasis on providing engrafted cells with the proper microenvironment for tissue development and maturation. Besides the 3D architecture biomaterial-based matrices provided to the cells, it is essential to provide the cells with necessary ECM--cell interactions. For instance, one group suggested to use decellularized ECM of porcine origin for the fabrication of injectable hydrogels and cardiac patches, successfully demonstrating encapsulation and culture of cardiac cells ([@B173]). Others suggested a composite of ECM components with synthetic, fibrillary, and elastic polymers, beneficial mostly at slowing the progression of scar formation and promoting angiogenesis ([@B29]). Similar ECM biochemical cues can be artificially added to semi-synthetic polymers. [@B166] suggested the covalent binding of RGD and HBP peptides to macroporous alginate scaffolds, promoting the striation and muscle fiber structure similar to that of a mature cardiac tissue. These scaffolds were further tested for their ability to promote cardiac regeneration from hESC-derived CMs, exhibiting improved functionality ([@B66]).

![Cardiac patch after explant. **(A)** Representative image of a dissected rat heart, 30 days post-implementation of an alginate cardiac patch. The cardiac patch consists of a macroporous alginate scaffold, incorporated with magnetic nanoparticles. The construct was seeded with human embryonic stem cell-derived cardiomyocytes, and cultivated for 24 h prior to implementation on top of an infarcted rat heart. Dashed line denotes cardiac patch borders; **(B)** photomicrograph of Masson's trichrome-stained section of the interface between implanted cardiac patch and host myocardium, 30 days post-transplantation. CP, cardiac patch; FS, fibrotic scar; HCM, host cardiac muscle. Scale bar is 100 μm. Images are courtesy of Mr. Edan Elovic.](fbioe-08-00126-g003){#F3}

Besides biochemical cues, anisotropic features were also shown to promote better tissue organization ([@B144]; [@B81]; [@B113]). Since both cardiac muscle and blood vessels are considered direction-oriented tissue constructs, different fabrication methods, including electrospinning of nanofiber structures, were investigated for influencing scaffold topography ([@B110]). For instance, polyurethane scaffolds were electrospun into aligned fibrous scaffolds, improving differentiation of murine ESC into CMs ([@B137]). A more sophisticated design used a hybrid scaffold, consisted of a network of conductive nanofibers and gelatin-based hydrogel, promoting aligned and elongated CM maturation ([@B198]). Recently, our group described a method of creating a magnetically aligned, 3D tissue culture matrix for tissue engineering comprised of three distinct classes of structural anisotropy -- anisotropic topographic features in the sub-micron scale, the directionality of the pore shape, and increased anisotropic stiffness in the direction of the magnetic alignment. Because magnetic forces govern the alignment phenomenon in the scaffold, all the anisotropic features shared a unidirectional structure that can synergistically benefit cultured cells ([@B113]).

The advances in cardiac patch research are not limited to the microenvironment scale. Cardiac patch designs have demonstrated improved cellular delivery rates and feasibility to achieve a clinically relevant cardiac graft in means of size and function ([@B150]; [@B169]; [@B104]). 3D bio-printing has also emerged as a strategy to assemble complex structures ([@B47]; [@B14]; [@B94]).

Other studies offer the use of exogenous stimuli to improve cardiac maturation and tissue organization *ex vivo*. After application of mechanical and electrical stimuli, iPSC-derived CMs were successfully forced to maturation and increased tissue contractility ([@B154]). Another approach suggested to use a magnetically responsive scaffold to induce mechanical stimulation, promoting ECs organization into blood vessels ([@B165]).

### Acellular Patches {#S4.SS3.SSS2}

Even though the presence of cells contributes to cardiac recovery (either directly or in a paracrine manner), the benefits of a cardiac patch are not limited to cellular components. To date, the most investigated biomaterial used for acellular patches is decellularized ECM. Studies conducted in small ([@B29]) and large ([@B8]) animal models have revealed that ECM-based patches not only provide the infarcted tissue with mechanical support but also alter ventricular wall remodeling, demonstrated consistent conduction across the patch, and even promoted neovascularization. Decellularized ECM patches, originated from porcine small intestinal submucosa are already commercially available (CorMatrix^®^) ([@B128]). CorMatrix^®^ patches remain flexible, exhibiting no calcification after 21 months post-implant; however, the formation of new CMs was not observed in these patches, suggesting this strategy mainly has a mechanical contribution ([@B131]). Another kind of acellular patches is designated to withstand the mechanical demands of a contracting heart. To this end, a unique auxetic pattern design was applied, allowing the patch to be stretched in multiple directions simultaneously ([@B79]). Using a chitosan--polyaniline composite to fabricate a conductive scaffold ([@B117]), the auxetic patch remained intact and attached, while maintaining left ventricular mass, presumably as a result of reduced wall stress ([@B79]). Further progress was recently achieved in applying acellular patches to restore cardiac function, as a first-in-man study was completed, demonstrating the feasibility of transendocardial injection of decellularized matrix (further discussed in the section "Clinical Trials of Biomaterial-Based Applications").

### Challenges Facing Cardiac Patch Implementation {#S4.SS3.SSS3}

The successful implementation of cardiac patches as a therapeutic strategy still faces several hurdles. In order to truly restore cardiac function, the cardiac patches must assimilate with the surrounding myocardium at three levels: physical and biochemical continuity, electrophysiological communication, and nutrient supply ([Figure 4](#F4){ref-type="fig"}).

![Challenges in cardiac patch implementation. Cardiac patches must integrate properly with host myocardium to properly improve cardiac function. For cell-seeded patches, sufficient nutrient supply by blood vessels is crucial for cell survival; biomaterials, as foreign objects, induce immunogenic response immediately after their introduction, impairing integration and leading to patch rejection; improper electrical coupling of the patch with host myocardium may result in arrhythmias; and cellular continuum, translated into biomechanical integrity, is also important for patch assimilation.](fbioe-08-00126-g004){#F4}

Even though cardiac patches improve cell viability and retention, cells engrafted through such constructs or through intracardiac injection could still provoke an immunogenic response, which ultimately will lead to allograft rejection ([@B199]). In addition, cardiac patch transplantation not accompanied with suppression of the host immune system will limit transplanted cell survival rate and therefore will result in failing integration ([@B112]).

It is also mandatory that designed scaffolds would be accessible for cell migration from areas close to the infarcted zones and allow the formation of blood vessels and nerves ([@B163]; [@B129]). Later, these networks must integrate properly with those of the host ([@B73]).

To date, grafts still present inferior functionality, mainly in action potential conductivity ([@B196]). Moreover, any graft transplanted would have to overcome the major restriction of integration. A graft not incorrectly integrated with the host heart tissue, both mechanically and electrically, could possibly lead to arrhythmia caused by unsynchronized electrophysiological signal transmission between the graft, the host myocardium, and the fibrotic interface in between ([@B20]). This problem was demonstrated in a study performed on primate hearts, using hESC-CM transplantation. Unlike smaller animal models, ventricular arrhythmias were observed consistently ([@B23]). This phenomenon could be related to the large distances the electrical and mechanical signals must travel, decreasing conductivity. Even in small animal models, cardiac patches were shown to fail at electrically integrating with the host, mainly due to the presence of a fibrotic scar barrier ([@B73]). Thus, cardiac patch designs must address these limitations to be clinically relevant. Future designs must take into consideration not only the patch's own functionality, but also its assimilation with host myocardium and synchronization over large distances.

Biomaterials, yet again, were recruited in order to overcome these hurdles. The main dogma suggests the use of porous scaffolds ([@B171]; [@B31]; [@B200]). Among previously mentioned advantages, such architecture also provides appropriate space and/or guiding routes for cells to penetrate the matrix. This principle could be exploited to dictate biomaterial degradation in a rate suitable for new tissue reconstruction ([@B10]). Nutrient supply and electrophysiological mediated integration could also be improved using smart biomaterial designs. For instance, VEGF containing scaffolds were designed to increase vascularization within the patch *in vivo* ([@B54]; [@B125]). Prevasularization of scaffolds was also suggested to improve mass transport into cardiac patches. To this end, ECM nanofibers and MSCs were used as a sheet designated to promote vascular constructs when co-cultured with ECs. They hypothesized that seeded MSCs will support the formation of microvessels and their structure through the secretion of angiogenic factors ([@B207]). In order to improve electrical coupling, [@B172] suggested to decorate decellularized matrices with gold NPs and nanowires, presenting stronger contractile force and lowering excitation threshold.

Biomaterials were also suggested as an alternative for stitching. By using near-infrared (NIR)-stimulated gold nanowires incorporated within the scaffold, engineered tissue was positioned on the myocardium and successfully attached ([@B111]). Another scaffold design suggested the use of a microneedle array composed of poly(vinyl alcohol), integrated with CSCs encapsulated within fibrin hydrogel ([@B180]). The proposed design was strong enough to allow microneedle penetration into the ischemic region, while also enabling cell migration into the microneedle array acting mostly in a paracrine manner. Altogether, the overviewed approaches indicate that biomaterials, alongside smart scaffold designs could potentially lead to true functional integration with surrounding tissue.

Controlled Release Platforms {#S4.SS4}
----------------------------

Platforms of controlled, sustained release are required for applications demanding local, time adjusted, and temporary delivery of bioactive molecules. Polymeric materials, capable of forming 2D and 3D matrices, have been superior candidates for this purpose for several decades ([@B91]; [@B69]; [@B134]). Since endogenous cardiac regeneration strategies usually aim to act locally, delivery systems impregnated within injectable hydrogels and cardiac patches are very appealing.

[@B191] illustrated the potential of a bioactive, injectable hydrogel to induce cardiac regeneration *in situ*. They developed an injectable hydrogel, based on high-affinity interactions between two oligosaccharides, modified with HA. This hydrogel system was capable of binding cholesterol with high affinity. For the application, miR-302 mimic, an identified CM proliferating inducer, was conjugated to cholesterol and mixed within the hydrogel. The resulting hydrogel exhibited a slow, sustained release profile over 3 weeks, thus demonstrating the potential to induce cardiac proliferation in the relatively long term. Indeed, they were able to show significant clonal expansion of CMs, following miR-302 releasing hydrogel injection into infarcted hearts of Confetti mice ([@B191]).

Injectable hydrogels were also used to improve cell survival and attenuate fibrotic responses immediately after MI. [@B160] speculated that the release of two GFs -- IGF-1 (considered cardioprotective) and hepatocyte growth factor (HGF; considered anti-fibrotic) will improve cardiac regeneration by targeting two key processes in scar formation. They used injectable alginate hydrogel consisting of affinity-binding AlgS, capable of binding both GFs. The injection of the proposed hydrogel into infarcted rat hearts had positive effects: reduced myocyte apoptosis and induction of CM proliferation attenuated infarct expansion and reduced fibrosis ([@B160]).

Cell-free cardiac patches were also demonstrated to be effective at inducing endogenous cardiac regeneration, based on the "paracrine effect." It is quite acceptable that one of the mechanisms in which cell-based therapies improve cardiac regeneration is through the secretion of cardioprotective factors, signaling surrounding cells in the infarct area. In one study, the researchers hypothesized that EVs derived from iPS or iPS-CM would have a similar effect. Therefore, they isolated these EVs *in vitro* and analyzed their miRNA content, supporting their assumptions. However, as mentioned, EVs are rapidly consumed by recipient cells, therefore their effect is time limited. In order to increase treatment efficacy, the isolated EVs were encapsulated in a cell-free collagen hydrogel, serving as a patch. The collagen hydrogel allowed a prolonged release of EVs up to 7 days *in vivo*. When the patch was applied in a rat MI model, it was able to reduce scar formation and apoptosis of CMs, while also promoting recovery of contractile functions, without any signs for arrhythmias ([@B105]). This system's main strength is its independence on any cellular component, reducing issues of immunogenicity and concerns regarding cellular viability and retention.

Clinical Trials of Biomaterial-Based Applications {#S5}
=================================================

Applications involving the use of biomaterials for cardiac regeneration have already entered clinical trials. The IK-5001 device, an injectable, bio-absorbable alginate hydrogel \[also known as bioabsorbable cardiac matrix (BCM)\], was tested for its safety and effectiveness for prevention of left ventricular remodeling (Bellerophon BCM LLC, [ClinicalTrials.gov](https://clinicaltrials.gov) identifier: NCT01226563). This trial was conducted in a randomized, double-blind, controlled setup, treating 303 patients worldwide. The interventional procedure included the injection of BCM into the infarct-related artery, 2--5 days after primary PCI. Safety endpoints for this research show no significant difference from saline injections; however, the BCM treatment did not reduce LV remodeling or major cardiovascular events after a 6-month follow-up. Among the reasons for this observation, the researchers specified the large infarct sizes selected (around 30% of LV area), in which remodeling could not possibly be prevented ([@B146]).

Another acellular, alginate hydrogel formulation examined in clinical trials is the Algisyl-LVR^TM^ device (LoneStar Heart Inc., Laguna Hills, CA, United States). Algisyl-LVR^TM^ was tested for its safety and efficacy in two separate clinical trials: One aimed to quantify its effect when combined with coronary artery bypass grafting ([ClinicalTrials.gov](https://clinicaltrials.gov) identifier: NCT0084796) and the second its employment as a method of left ventricular augmentation and restoration to treat patients with advanced chronic HF ([ClinicalTrials.gov](https://clinicaltrials.gov) identifier: NCT01311791). In both trials the treatment included an open-heart procedure, followed by 10--15 implant injections into the left ventricular heart muscle. The first clinical trial showed remarkable improvement in cardiac function, including elevated ejection fraction (from 32 ± 8 to 47 ± 17% after 3 months), decreased end-systolic and diastolic volumes, and an increase in average wall thickness compared with control saline injections ([@B95]). In the second, randomized and controlled study, known as the AUGMENT-HF trial, effectiveness of treatment was assessed. Seventy-eight patients with dilated cardiomyopathy were selected as treatment group, and exhibited significant improvement in exercise capacity and symptoms (elevated Peak VO~2~ and longer distance in 6-min walk test) compared to control. However, these results should be considered with caution, as this trial was subjected to bias due to lack of blinding for the assignment of patients to the surgical procedure ([@B5]).

VentriGel^TM^ (Ventrix, Inc., San Diego, CA, United States), an acellular, porcine-cardiac ECM hydrogel, was also examined in a recently published phase I clinical trial ([ClinicalTrials.gov](https://clinicaltrials.gov) identifier: NCT02305602). In this study, researchers evaluated the safety and feasibility of VentriGel^TM^. The hydrogel was delivered *trans*-endocardially within a time window between 60 days to 3 years since the first, large ST elevation MI. The outcomes of this first-in-man trial highlighted the safety and feasibility of this treatment, while also showing improvement in exercise capacity examined by a 6-min walk test, even though this study was not designed to test effectiveness of treatment ([@B185]). Even though the collective results of clinical trials involving injection of hydrogels alone highlight the feasibility and safety of this method at improving cardiac function after MI, there is still no sufficient evidence for the capability of pristine hydrogels to promote endogenous cardiac regeneration by themselves.

CorMatrix^®^ ECM cardiac patches, which recently received FDA approval, were tested in clinical trials (CorMatrix Cardiovascular, Inc., [ClinicalTrials.gov](https://clinicaltrials.gov) identifier: NCT02887768), claimed to promote endogenous cardiac regeneration. Pre-clinical studies with CorMatrix^®^ patches for epicardial infarct repair in a pig model supported this claim, presenting neovascularization in the interface between the infarct and the patch ([@B124]). Yet, in a study performed in children with congenital heart disease, there was no evidence for endogenous ingrowth of native cardiac muscle within 21 months ([@B131]). At the present time point, clinical trials using CorMatrix patches have been designed to evaluate safety only rather than their effectiveness.

Recently, the results of a phase I clinical trial were published, determining the safety and efficacy of transplanting cardiac-committed progenitor cells derived from hESCs, using a fibrin cardiac patch ([ClinicalTrials.gov](https://clinicaltrials.gov) identifier: NCT02057900). The fibrin cardiac patch, 20 cm^2^ in size seeded with *ex vivo* differentiated cells, was inserted inside a "pocket" under the pericardium. The results of this trial mostly demonstrated the capability to produce highly purified hESC-derived cardiac progenitor cells, without evidence of tumor formation or arrhythmias ([@B122]). Although the feasibility to produce clinical-grade hESC-CM for transplantation was demonstrated, clinical trials assessing efficacy were not yet conducted.

Conclusion, Limitations, and Future Perspectives {#S6}
================================================

Biomaterial-based strategies offer a wide range of solutions and additives to various cardiac regeneration therapeutic approaches, making them more and more effective and clinically relevant. Biomaterials may be utilized as a vehicle for efficient delivery of regeneration-inducing small molecules and/or cells, to act as matrix guiding cell maturation (*in vitro* and *in situ*), and perform as a platform for sustained drug delivery, achieving cardiac regeneration based on the paracrine effect hypothesis. The common principle behind the use of biomaterials is their ability to function as potential mediators between the therapeutic agents and their target, while also having beneficial influence on their own.

Even though biomaterials were already tested in clinical trials for their safety, showing encouraging results and implying improvement in cardiac function, there are still some findings in pre-clinical and clinical trials that should not be overlooked. The most important issue regards foreign body response of the host to biomaterials used as medical devices. An adverse immunogenic response is common to all the biomaterial applications discussed in this review. In general, when a biomaterial, either natural or synthetic, is in contact with host tissue, it induces a response of the innate immune system, and later the adaptive immune system. Degradation products of implanted biomaterials also activate immune system components. The development of an excessive inflammatory response might severely impair the efficacy of biomaterial applications, since the endpoint of this process is fibrotic encapsulation of the device, thus minimizing its surface interplay with the host tissue and if the device is a drug delivery system, the encapsulation would affect the release profile of the drug from the device ([@B114]). Therefore, it is extremely important to evaluate host response when applying biomaterial-based strategies for cardiac regeneration, mostly due to the adverse inflammatory response following MI. Some of the presented strategies are more susceptible to fibrotic encapsulation, mostly those involving synthetic biomaterials or containing allogeneic cellular components, thus these attributes should be taken into consideration. A possible strategy to make cellular biomaterials more tolerated is the application of immunosuppressive agents combined within the therapeutic approach ([@B136]).

Even though biomaterials are already established members in many therapeutic approaches for cardiovascular diseases, such applications have not yet reached their full potential, as there is still more room for improvements in means of mechanical stability, tolerance to immunogenic host responses, and proper integration and functional improvement with biomaterial applications. For example, the greatest challenge cardiac patches are still facing is associated with their assimilation with host myocardium. Based on the success of biomaterials to perform as drug delivery platforms and construct a highly sophisticated cardiac patch design, it is also possible that biomaterials could be the answer for that issue as well, by combining the two. For instance, incorporation of a biomaterial-based drug delivery system within a fully developed cardiac patch, acting simultaneously to treat the harmful consequences of MI while also having the potential to restore cardiac function by improving integration with the remaining, healthy cardiac tissue. Since none of the applications can fully regenerate an entire new muscle by itself, this combination could have a synergistic effect on cardiac regeneration.
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